Amylyx Pharmaceuticals Announces Publication Of Data From The Phase 2 PEGASUS Trial Showing The Effects Of AMX0035 On Cerebrospinal Fluid Biomarkers Of Core Alzheimer's Disease Pathology And Neurodegeneration
Portfolio Pulse from Benzinga Newsdesk
Amylyx Pharmaceuticals announced the publication of data from the Phase 2 PEGASUS trial, showing that their drug AMX0035 affects cerebrospinal fluid biomarkers related to Alzheimer's disease and neurodegeneration. The findings were published in the journal Alzheimer's & Dementia: Translational Research & Clinical Interventions.
August 12, 2024 | 1:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amylyx Pharmaceuticals published promising data from the Phase 2 PEGASUS trial, showing that AMX0035 affects Alzheimer's disease biomarkers. This could positively impact the stock price in the short term.
The publication of positive trial data in a peer-reviewed journal is likely to boost investor confidence and could lead to a short-term increase in the stock price of Amylyx Pharmaceuticals.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100